FANCC and Fanconi anemia: Early xenograft studies by van der Heijden et al showed a more pronounced response of FANCC and BRCA2-deficient pancreatic tumors to mitomycin C relative to Fanconi anemia proficient xenografts (van der Heijden et al., 2005).